Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Accumulated Expenses (2017 - 2024)

KalVista Pharmaceuticals' Accumulated Expenses history spans 10 years, with the latest figure at $8.3 million for Q4 2024.

  • For Q4 2024, Accumulated Expenses changed N/A year-over-year to $8.3 million; the TTM value through Dec 2024 reached $8.3 million, changed N/A, while the annual FY2024 figure was $12.4 million, N/A changed from the prior year.
  • Accumulated Expenses for Q4 2024 was $8.3 million at KalVista Pharmaceuticals, up from $7.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $12.4 million in Q2 2024 and bottomed at $2.2 million in Q1 2021.
  • The 4-year median for Accumulated Expenses is $5.8 million (2020), against an average of $5.9 million.
  • The largest annual shift saw Accumulated Expenses soared 696.13% in 2020 before it tumbled 60.19% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $6.9 million in 2020, then plummeted by 67.76% to $2.2 million in 2021, then soared by 72.16% to $3.9 million in 2023, then surged by 116.35% to $8.3 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Accumulated Expenses are $8.3 million (Q4 2024), $7.0 million (Q4 2024), and $3.2 million (Q3 2024).